Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
4.540
+0.150 (3.42%)
At close: Sep 19, 2025, 4:00 PM EDT
4.400
-0.140 (-3.08%)
After-hours: Sep 19, 2025, 7:52 PM EDT
Kalaris Therapeutics Stock Forecast
KLRS's stock price has decreased by -74.03% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Kalaris Therapeutics stock has a target of 23, which predicts a 406.61% increase from the current stock price of 4.54.
Price Target: $23 (+406.61%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kalaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jul '25 | Aug '25 | Sep '25 |
---|---|---|---|
Strong Buy | 0 | 0 | 1 |
Buy | 1 | 1 | 1 |
Hold | 0 | 0 | 0 |
Sell | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 |
Total | 1 | 1 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Raymond James | Raymond James | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +406.61% | Sep 3, 2025 |
William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Apr 8, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.96
from -10.44
EPS Next Year
-2.70
from -3.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 |
---|---|---|---|
High | n/a | n/a | |
Avg | n/a | n/a | |
Low | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | |
Avg | - | - | |
Low | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -2.79 | -2.67 | |
Avg | -3.96 | -2.70 | |
Low | -4.44 | -2.74 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | |
Avg | - | - | |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.